The EC approval also now means that Libtayo can be used to treat certain patients across four types of cancer within the European Union: advanced squamous cell carcinoma (SCC), advanced basal cell ...

It's been cleared for second-line use in patients who have progressed or are intolerant to hedgehog inhibitor therapy. Libtayo was the sixth PD-L/PD-L1 inhibitor to reach the market, starting out ...

Besides Wall Street's top -and-bottom-line estimates for Regeneron (REGN), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the ...

A study in Nature Communications found that older cancer patients have similar outcomes with immune checkpoint inhibitors as ...

Libtayo sales are being driven by growth in demand ... The regulatory body set a target action date of Aug. 19, 2025, following the use of a Priority Review voucher. Here are some drug/biotech ...

Biotech giant Regeneron Pharmaceuticals, Inc. REGN is slated to report first-quarter 2025 results on April 29, 2025. The ...

today announced that Ig - Immuneering plans to evaluate IMM-1-104 in combination with Libtayo in patients with advanced non-small cell lung cancer in its ongoing Phase 2a trial – - Data ...

What is ivermectin, and what are its approved uses? Why do some people believe that it can be used beyond its approved uses? What are potential harms of taking this medication? And how should ...